RCUS - Arcus Biosciences, Inc.
NYSE
->
Healthcare
->
Biotechnology
Hayward,
United States
Type: Equity
RCUS price evolution
RCUS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $127 | $184 | $230 | $238 |
| Short term investments | $632 | $615 | $700 | $716 |
| Net receivables | $38 | $52 | $34 | $33 |
| Inventory | ||||
| Total current assets | $831 | $882 | $986 | $1015 |
| Long term investments | $107 | $151 | $80 | $90 |
| Property, plant & equipment | $51 | $50 | $45 | $37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $264 | $309 | $234 | $239 |
| Total investments | $739 | $766 | $780 | $806 |
| Total assets | $1095 | $1191 | $1220 | $1254 |
| Current liabilities | ||||
| Accounts payable | $17 | $17 | $12 | $28 |
| Deferred revenue | $398 | $429 | $433 | $427 |
| Short long term debt | ||||
| Total current liabilities | $184 | $200 | $180 | $179 |
| Long term debt | ||||
| Total noncurrent liabilities | $449 | $471 | $474 | $475 |
| Total debt | ||||
| Total liabilities | $633 | $671 | $654 | $654 |
| Shareholders' equity | ||||
| Retained earnings | -$849 | -$768 | -$697 | -$622 |
| Other shareholder equity | -$3 | -$4 | -$4 | |
| Total shareholder equity | $462 | $520 | $566 | $600 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $127 | $206 | $150.92 | $173.62 |
| Short term investments | $632 | $803 | $351.39 | $555.23 |
| Net receivables | $38 | $39 | $744.6 | $1.05 |
| Inventory | ||||
| Total current assets | $831 | $1067 | $1261.75 | $735.82 |
| Long term investments | $107 | $129 | $181.99 | $6.44 |
| Property, plant & equipment | $51 | $135 | $137.42 | $23.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $264 | $278 | $330.15 | $36.48 |
| Total investments | $739 | $932 | $533.38 | $561.67 |
| Total assets | $1095 | $1345 | $1591.9 | $772.29 |
| Current liabilities | ||||
| Accounts payable | $17 | $20 | $10.26 | $15.68 |
| Deferred revenue | $398 | $452 | $564.22 | $197.4 |
| Short long term debt | ||||
| Total current liabilities | $184 | $193 | $166.08 | $121.67 |
| Long term debt | $116.89 | $15.24 | ||
| Total noncurrent liabilities | $449 | $495 | $584.36 | $148.32 |
| Total debt | $116.89 | $15.24 | ||
| Total liabilities | $633 | $688 | $750.45 | $269.99 |
| Shareholders' equity | ||||
| Retained earnings | -$849 | -$542 | -$275.35 | -$328.18 |
| Other shareholder equity | -$7 | -$1.26 | $0.04 | |
| Total shareholder equity | $462 | $657 | $841.45 | $502.3 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $31 | $32 | $29 | $25 |
| Cost of revenue | ||||
| Gross Profit | $31 | $32 | $29 | $25 |
| Operating activities | ||||
| Research & development | $93 | $82 | $84 | $81 |
| Selling, general & administrative | $29 | $30 | $28 | $30 |
| Total operating expenses | $122 | $112 | $112 | $111 |
| Operating income | -$91 | -$80 | -$83 | -$86 |
| Income from continuing operations | ||||
| EBIT | -$80 | -$69 | -$74 | -$78 |
| Income tax expense | $1 | $2 | $1 | $2 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$81 | -$71 | -$75 | -$80 |
| Income (for common shares) | -$81 | -$71 | -$75 | -$80 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $117 | $112 | $382.88 | $77.52 |
| Cost of revenue | ||||
| Gross Profit | $117 | $112 | $382.88 | $77.52 |
| Operating activities | ||||
| Research & development | $340 | $288 | $256.35 | $159.35 |
| Selling, general & administrative | $117 | $104 | $72.29 | $42.4 |
| Total operating expenses | $457 | $392 | $328.63 | $201.75 |
| Operating income | -$340 | -$280 | $54.25 | -$124.23 |
| Income from continuing operations | ||||
| EBIT | -$301 | -$266 | $54.65 | -$122.86 |
| Income tax expense | $6 | $1 | $1.81 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$307 | -$267 | $52.83 | -$122.86 |
| Income (for common shares) | -$307 | -$267 | $52.83 | -$122.86 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$81 | -$71 | -$75 | -$80 |
| Operating activities | ||||
| Depreciation | $5 | $3 | $4 | $4 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18 | $18 | $18 | $19 |
| Total cash flows from operations | -$88 | -$63 | -$57 | -$98 |
| Investing activities | ||||
| Capital expenditures | -$6 | -$10 | -$5 | -$3 |
| Investments | $34 | $21 | $31 | $132 |
| Total cash flows from investing | $28 | $11 | $26 | $129 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | $6 | $23 | $1 |
| Net borrowings | ||||
| Total cash flows from financing | $3 | $6 | $23 | $1 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$57 | -$46 | -$8 | $32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$307 | -$267 | $52.83 | -$122.86 |
| Operating activities | ||||
| Depreciation | $16 | $14 | $7.06 | $4.19 |
| Business acquisitions & disposals | -$3 | |||
| Stock-based compensation | $73 | $65 | $54.53 | $21.82 |
| Total cash flows from operations | -$306 | $438 | -$256.17 | $111.17 |
| Investing activities | ||||
| Capital expenditures | -$24 | -$6 | -$26.08 | -$3.06 |
| Investments | $218 | -$404 | $22.21 | -$431.31 |
| Total cash flows from investing | $194 | -$413 | -$3.87 | -$434.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $33 | $23 | $232.34 | $438.68 |
| Net borrowings | ||||
| Total cash flows from financing | $33 | $33 | $237.34 | $438.68 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$79 | $58 | -$22.7 | $115.48 |
News
Fundamentals
| Market cap | $1.12B |
|---|---|
| Enterprise value | $993.42M |
| Shares outstanding | 75.50M |
| Revenue | $117.00M |
|---|---|
| EBITDA | -$285.00M |
| EBIT | -$301.00M |
| Net Income | -$307.00M |
| Revenue Q/Q | -7.89% |
| Revenue Y/Y | 4.46% |
| P/E ratio | -3.65 |
|---|---|
| EV/Sales | 8.49 |
| EV/EBITDA | -3.49 |
| EV/EBIT | -3.30 |
| P/S ratio | 9.58 |
| P/B ratio | 2.43 |
| Book/Share | 6.12 |
| Cash/Share | 1.68 |
| EPS | -$4.07 |
|---|---|
| ROA | -25.80% |
| ROE | -57.17% |
| Debt/Equity | 1.37 |
|---|---|
| Net debt/EBITDA | -1.78 |
| Current ratio | 4.52 |
| Quick ratio | 4.52 |